Commercialization of the Medical Business Centered on China
First written in FY2017. 2 of 3 entries say "Reframed", first in FY2021. Latest entry: FY2023.
Ushio moved to the "Worse" side of this theme in 2021.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Reframed".
- FY2023ReframedAnnual report
「With a view to expanding the business over the long term, we have positioned it as a business under development in the current medium-term management plan. We aim to develop it into a business area comparable to the Industrial Process and Visual Imaging businesses, selecting and advancing promising business themes that enable us to propose solutions centered on the optical technologies of our group.」
The business has been reorganized from the previous China-centered medical commercialization strategy into a market-oriented portfolio designed to develop Life Science into a core business over the medium to long term. - FY2021ReframedAnnual report
「We are also narrowing the business focus to 3 areas: component inspection equipment, Organs on Chip, and infection prevention solutions. We are strengthening initiatives, including through active investment, with the goal of achieving profitability in several years.」
The policy has been made more specific, shifting from the previous explanation of a China-centered medical business to commercialization focused on 3 areas: component inspection equipment, Organs on Chip, and infection prevention solutions. - FY2017First statedAnnual report
「Within the equipment business, we will promote commercialization of the medical business by strengthening business development based on existing products and pursuing a regional strategy centered on China.」
A policy of promoting commercialization of the medical business through the use of existing products and a China-centered regional strategy has been presented for the first time.